Trial · NCT00562627
Efficacy of Multimodal Peri- and Intraarticular Drug Injections in Total Knee Arthroplasty
NCT00562627, Phase 4, Completed, Asker & Baerum Hospital; results first posted 2011-08-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Multimodal Peri- and Intraarticular Drug Injections in Total Knee Arthroplasty. Trials, record NCT00562627. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00562627
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Multimodal Peri- and Intraarticular Drug Injections in Total Knee Arthroplasty
- NCT number
- NCT00562627
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 102 participants, actual
- Lead sponsor
- Asker & Baerum Hospital
- Conditions
- Osteoarthritis of the Knee
- Interventions
- ropivacaine, adrenaline, ketorolac, morphine, fentanyl, bupivacaine
- First posted
- 2007-11-22
- Last updated
- 2011-08-08
- Other registries' IDs
- eudract:2007-003030-41
- Results first posted
- 2011-08-08
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pain at Rest (VAS) | 48 hours postoperative | VAS (pain at rest) 0-100 mm. VAS 0 mm means no pain and VAS 100 mm means maximal pain. |
| Secondary | Opioid Use | 48 hours postoperative | Morphine used by patient controlled analgesia. Amount of used morphine during the first 48 hours after surgery were documented in the CRF by the pain nurses. |
| Secondary | Time to Readiness for Discharge | up to 10 days postoperative | Each postoperative day, discharge readiness was assessed by an orthopaedic surgeon, a pain nurse, a ward nurse, and a physiotherapist according to the following criteria: no evidence for surgical complications, VAS pain at rest ≤30 mm which is controlled by oral analgesics, ability to eat and drink, ability to walk with elbow crutches, and ability to climb ≥8 stairs. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| SECONDARY | Opioid Use | 48 hours postoperative | mg | MEAN | |
| PRIMARY | Pain at Rest (VAS) | 48 hours postoperative | Units on a scale | MEAN | |
| SECONDARY | Time to Readiness for Discharge | up to 10 days postoperative | days | MEAN |
Source ClinicalTrials.gov
Results by group9
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Opioid Use | LIA IV (Local Infiltration Analgesia, Intravenous) | 77 | Standard Deviation 39 | mg | |
| Opioid Use | LIA IA, (Local Infiltration Analgesia, Intra-articular) | 49 | Standard Deviation 36 | mg | |
| Opioid Use | Epidural | 54 | Standard Deviation 43 | mg | |
| Pain at Rest (VAS) | LIA IV (Local Infiltration Analgesia, Intravenous) | 18 | Standard Deviation 15 | Units on a scale | |
| Pain at Rest (VAS) | LIA IA, (Local Infiltration Analgesia, Intra-articular) | 12 | Standard Deviation 13 | Units on a scale | |
| Pain at Rest (VAS) | Epidural | 30 | Standard Deviation 29 | Units on a scale | |
| Time to Readiness for Discharge | LIA IV (Local Infiltration Analgesia, Intravenous) | 4 | Standard Deviation 1.3 | days | |
| Time to Readiness for Discharge | LIA IA, (Local Infiltration Analgesia, Intra-articular) | 3.5 | Standard Deviation 0.7 | days | |
| Time to Readiness for Discharge | Epidural | 5.5 | Standard Deviation 1.6 | days |
Source ClinicalTrials.gov
Participant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | LIA IV (Local Infiltration Analgesia, Intravenous) | 34 | |
| Overall Study | STARTED | LIA IA, (Local Infiltration Analgesia, Intra-articular) | 34 | |
| Overall Study | STARTED | Epidural | 34 | |
| Overall Study | COMPLETED | LIA IV (Local Infiltration Analgesia, Intravenous) | 33 | |
| Overall Study | COMPLETED | LIA IA, (Local Infiltration Analgesia, Intra-articular) | 33 | |
| Overall Study | COMPLETED | Epidural | 33 | |
| Overall Study | NOT COMPLETED | LIA IV (Local Infiltration Analgesia, Intravenous) | 1 | |
| Overall Study | NOT COMPLETED | LIA IA, (Local Infiltration Analgesia, Intra-articular) | 1 | |
| Overall Study | NOT COMPLETED | Epidural | 1 |
Source ClinicalTrials.gov
Adverse events3
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Knee infection | Musculoskeletal and connective tissue disorders | LIA IV (Local Infiltration Analgesia, Intravenous) | 0 | 33 | 0 |
| serious | Knee infection | Musculoskeletal and connective tissue disorders | LIA IA, (Local Infiltration Analgesia, Intra-articular) | 0 | 33 | 0 |
| serious | Knee infection | Musculoskeletal and connective tissue disorders | Epidural | 1 | 33 | 1 |
Source ClinicalTrials.gov
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | LIA IV (Local Infiltration Analgesia, Intravenous) | ||
| Total, all-cause mortality | LIA IA, (Local Infiltration Analgesia, Intra-articular) | ||
| Total, all-cause mortality | Epidural | ||
| Total, other adverse events | LIA IV (Local Infiltration Analgesia, Intravenous) | 0 | 33 |
| Total, other adverse events | LIA IA, (Local Infiltration Analgesia, Intra-articular) | 0 | 33 |
| Total, other adverse events | Epidural | 0 | 33 |
| Total, serious adverse events | LIA IV (Local Infiltration Analgesia, Intravenous) | 0 | 33 |
| Total, serious adverse events | LIA IA, (Local Infiltration Analgesia, Intra-articular) | 0 | 33 |
| Total, serious adverse events | Epidural | 1 | 33 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 20736233 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00562627
GET https://conductscience.org/api/trials/v1/NCT00562627/registered